Comparative Pharmacology
Head-to-head clinical analysis: HALDOL versus INAPSINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALDOL versus INAPSINE.
HALDOL vs INAPSINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol is a typical antipsychotic that blocks dopamine D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways, reducing positive symptoms of schizophrenia. It also has moderate affinity for sigma receptors and weak affinity for serotonin 5-HT2, alpha-adrenergic, and histamine H1 receptors.
Butyrophenone antipsychotic; antagonizes dopamine D2 receptors in the CNS, also exhibits alpha-adrenergic blocking activity.
Initial: 1-5 mg PO/IM twice daily; titrate up to 5-10 mg/day. Acute agitation: 5-10 mg IM every 1-8 hours. Maintenance: 5-10 mg/day PO/IM. Maximum: 100 mg/day.
IM: 2.5-10 mg every 3-4 hours as needed; IV: 2.5-10 mg slow IV push (over 2-3 minutes), repeat every 30-60 minutes as needed; maximum total dose 20 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 21 hours (range 12–37 hours). Extended half-life in chronic administration supports once-daily dosing; dose adjustments required in hepatic impairment.
Terminal elimination half-life is 10-22 hours (mean 14.5 hours) in adults; may be prolonged in elderly or patients with hepatic impairment.
Renal (approximately 40%, with 1% unchanged; remainder as metabolites) and fecal (approximately 60%, primarily via bile).
Primarily renal (50-70% as unchanged drug and metabolites); biliary/fecal excretion accounts for approximately 20-30%.
Category C
Category C
Antipsychotic
Antipsychotic